Ethypharm, VIATRIS' tramadol Flashtab
French drug-delivery firm Ethypharm and VIATRIS (formerly Asta Medica)of Germany have entered into a collaboration to develop an innovate oral formulation of tramadol for the relief of moderate-to-severe pain, using the former's Flashtab technology.
Under the terms of this deal, Ethypharm is responsible for product development, production and registration, and VIATRIS will market and distribute the novel Flashtab version of tramadol broadly in Europe. The French firm will receive undisclosed upfront and milestone payments from VIATRIS, as well as royalties on sales.
Tramadol is a synthetic, centrally-acting analgesic, structurally related to codeine and morphine. It is the fourth most-commonly prescribed analgesic worldwide for moderate-to-severe pain, and sales of the immediate-release form in Europe run at about 107 million euros ($103.8 million) a year, of which tramadol Flashtab hopes to gain a 25% market share in 2005.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze